Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Headache Clear all
Completed No phase listed Observational Results available

Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)

NCT06138756
View directory record Official record
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
6 Years to 12 Years
Enrollment
293 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
124
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia

NCT05536050
View directory record Official record
Conditions
Chronic Migraine, Fibromyalgia, New Daily Persistent Headache
Interventions
Migraine diary and Questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Results available

Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs

NCT00386880
View directory record Official record
Conditions
Migraine
Interventions
Sounds
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

NCT01842633
View directory record Official record
Conditions
Pain
Interventions
Paracetamol and Caffeine, Ibuprofen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Phase 4 Interventional

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

NCT07301008
View directory record Official record
Conditions
Migraine, Trigger Induced Migraine
Interventions
Rimegepant 75 MG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

CBT Depression Intervention for Co-Occurring Chronic Headache

NCT02870725
View directory record Official record
Conditions
Depression, Headaches Chronic, Migraine Disorders
Interventions
CBT Individual Psychotherapy
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Athens, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Evaluation of a Novel Device for Treatment of Migraine Headache

NCT03361423
View directory record Official record
Conditions
Migraine Without Aura, Migraine With Aura
Interventions
Nerivio Migra-1 active device, Nerivio Migra-1 Sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

NCT00904098
View directory record Official record
Conditions
Menstrual Migraine (MM) Headaches
Interventions
Frovatriptan, Usual Care
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
21
States / cities
Stratford, Connecticut • Clearwater, Florida • Jacksonville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Mobile Subthreshold Exercise Program for Concussion--R01

NCT04688255
View directory record Official record
Conditions
Concussion, Brain, Concussion, Mild, Brain Injuries, Traumatic, Persistent Post Traumatic Headache, Post-Concussion Syndrome, Post-Concussive Syndrome, Chronic
Interventions
MSTEP, Stretching
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

NCT03159000
View directory record Official record
Conditions
Migraine
Interventions
Saline, lidocaine/bupivacaine
Drug · Combination Product
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Treatment for Migraine and Mood

NCT05576467
View directory record Official record
Conditions
Migraine, Depressive Symptoms
Interventions
MBCT-Telephone, MBCT-Video, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Amanda Shallcross
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transnasal Therapy for Acute Migraine Attack

NCT04129567
View directory record Official record
Conditions
Migraine Disorders
Interventions
Humidified oxygen, Dry oxygen, Humidified air, Dry air
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

NCT04408794
View directory record Official record
Conditions
Acute Migraine
Interventions
Zavegepant (BHV-3500)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
67
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational

Nerivio Long-term Usage in Patients With Migraine

NCT06738056
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Mindfulness and Mechanisms of Pain Processing in Adults With Migraines

NCT02695498
View directory record Official record
Conditions
Migraine
Interventions
Mindfulness Based Stress Reduction, Migraine/stress Education
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Evaluation of a Wearable Device for Acute Treatment of Migraines

NCT07015125
View directory record Official record
Conditions
Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

NCT04179474
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Erenumab, Galcanezumab
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Springfield, Missouri • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
View directory record Official record
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

Effects of a Multispecies Probiotic on Migraine

NCT04696458
View directory record Official record
Conditions
Migraine, Irritable Bowel Syndrome, Headache, Migraine
Interventions
Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo
Dietary Supplement · Other
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Sphenopalatine Ganglion Blocks RCT

NCT03666663
View directory record Official record
Conditions
Migraine
Interventions
Lidocaine, Bupivacaine, Ropivacaine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

NCT01813591
View directory record Official record
Conditions
Chronic Migraine
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Treatment of Chronic Migraine Headaches.

NCT03220113
View directory record Official record
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 11, 2026, 8:23 AM EDT